A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER
Latest Information Update: 13 Apr 2026
At a glance
- Drugs 707 3SBio (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Symbiotic-Lung-14
- Sponsors Pfizer
Most Recent Events
- 23 Mar 2026 New trial record